Organizational Chart International Technology Transfer General Information Career Opportunities


Spacer

 
Licensing & Royalties
spacer
 

Licensing Opportunities

Technology Abstracts

Print This Abstract Apply Questions ?
Multiplex Microarray for Simultaneous Detection of Hepatitis C Virus, Hepatitis B Virus, and Human Immunodeficiency Virus Type-1

Description of Invention:
Available for licensing and commercial development are patent rights that cover a specific and sensitive microarray (TTD -V-1) and multiplex assay for the simultaneous detection and discrimination of Hepatitis C Virus (HCV), Hepatitis B Virus (HBV) and Human Immunodeficiency Virus Type-1 (HIV-1), which include both RNA and DNA genomes. Four specific probes (30-45 bp oligonucleotides) for each of these three viruses as well as the two internal controls were designed. Totally, each microarray consists of 20 probes immobilized on silylated glass slides. The single-stranded Cy5-labeled samples for microarray hybridization were obtained from labeling the amplicons using primer extension thermocycling. The multiplex microarray assay was able to detect and discriminate as low as 3 copies of genotypes A, B, C, D, and 10 copies of genotype E of HBV, 10 copies of HCV (genotype 1b), and 20 copies of HIV-1 (group M, subtype B) in a single multiplex reaction. The microarray assay could also detect the coexistence of two or three of these viruses and discriminate them simultaneously. The results of this study demonstrated the feasibility and performance of microarray-based multiplex detection of the three viruses, HCV, HBV, and HIV-1 in comparison with conventional individual PCR and gel electrophoresis technique.

Inventors:
Chu Chieh Xia (FDA)
Gerardo Kaplan (FDA)
Hira Nakhasi (FDA)
Amy Yang (FDA)
Raj Puri (FDA)

Patent Status:
DHHS Reference No. E-077-2006/0 --
U.S. Provisional Application No. 60/759,214 filed 17 Jan 2006

Licensing Status:
Available for non-exclusive or exclusive licensing.

Collaborative Research Opportunity:
The Food and Drug Administration's Center for Biologics Evaluation and Research (CBER) is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. Please contact Beatrice Droke, Technology Development Coordinator, FDA, (301) 827-7008 for more information.


Portfolios:
Infectious Diseases

Infectious Diseases -Diagnostics-Viral-AIDS (only)
Infectious Diseases -Diagnostics-Viral-Non-AIDS (only)
Infectious Diseases -Diagnostics


For Additional Information Please Contact:
Michael Shmilovich J.D.
NIH Office of Technology Transfer
6011 Executive Blvd, Suite 325
Rockville, MD 20852-3804
Phone: (301) 435-5019
Email: shmilovm@mail.nih.gov
Fax: (301) 402-0220


Web Ref: 1351

Updated: 6/06

 

 
 
Spacer